Management  :  Alliances & Partnerships  :  Investors : Board of Directors  :  Advisors

Oxford Institute of Biomedical Engineering (IBME)

The IBME, situated on the University of Oxford’s medical research campus, is due to open during the 2007-8 academic year. The IBME will provide purpose-built laboratories with the latest equipment for research, shared common support facilities, a core of securely-funded staff, and the right setting to promote collaboration between medical, biological and physical scientists and engineers.

Particle Therapeutics is a University of Oxford spin-out company, which has developed from research undertaken at the Institute of Biomedical Engineering.

www.ibme.ox.ac.uk

Oxford Centre for Diabetes, Endocrinology & Metabolism (OCDEM)

OCDEM is a pioneering centre which combines clinical care, research and education in diabetes, endocrine annd metabolic diseases. By promoting world-class research, it aims to enhance understanding of these diseases and to accelerate the search for new treatments and cures.

OCDEM will design our clinical trials, which will be undertaken both at OCDEM in the UK, and at a site in the US.

www.ocdem.com

Battelle Institute, Columbus, Ohio

Battelle is a global science and technology enterprise that develops and commercializes technology and manages laboratories for customers. Headquartered in Columbus, Ohio, Battelle has a vast science and technology reach. Battelle, with the national labs it manages or co-manages, oversees 19,000 staff members and conducts $3.7 billion in annual research and development. Battelle provides solutions and develops innovative products, helping commercial customers leverage technology into a competitive advantage. Battelle also teams with more than 800 federal, state and local government agencies, providing cost-effective science and technology in the areas of national security, homeland defence, health and life sciences, energy, transportation and environment.

The Battelle Institute will perform our pre-clinical animal studies under GLP.

www.battelle.org

Department of Pharmaceutics, Friedrich-Alexander University, Erlangen, Germany

The Department of Pharmaceutics of the Friedrich-Alexander University in Erlangen specializes in the production and analytics of drug delivery systems. The central research interest is the spray-drying of peptides and proteins to form stable, protein-loaded, fine particles for pulmonary or parenteral application. The Department possesses a large amount of particle production equipment and most of the analytical methods to examine the structure and stability of peptides and proteins during processing and storage. Chair of the Department is Professor Geoffrey Lee, an internationally-known specialist in spray-drying and topical dosage forms. Professor Lee is a consultant to Particle Therapeutics and was formerly a long-time consultant to PowderJect.

The Department’s expertise in powder formulation will contribute to our production of glucagon particles.

www.pharmtech.uni-erlangen.de

Anesiva

Anesiva, Inc. (Nasdaq: ANSV) is a late-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain management.

The company’s first product, Zingo™ (lidocaine hydrochloride monohydrate) powder intradermal injection system, was approved by the U.S. Food and Drug Administration (FDA) in August 2007 to reduce the pain associated with venous access procedures, such as IV insertions or blood draws, in children ages three to 18.

Anesiva and Particle Therapeutics have entered into an agreement granting us a licence to incorporate Anesiva’s drug delivery technology into our needle-free, transdermal delivery system for glucagon. For further details, please click here.

www.anesiva.com